This inventor holds 127 USPTO granted patents and 18 published patent applications, plus 21 CIPO patents and 26 EPO patents, primarily in Immunotherapy Research (CPC class 5303873). Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, The United States of America as Represented by the Department of Health, Duke University. Active years: 1983-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Inventors with similar research interests:
Location History:
- Potamac, MD (US) (2008)
- Bethesda, MD (US) (2014)
- Potomac, MD (US) (1983 - 2021)
- Chevy Chase, MD (US) (2022 - 2023)
Company Filing History:
77 out of 3,696 
32 out of 1,217 
10 out of 2,084 
Years Active: 1983-2026
Areas of Expertise:
Title: Innovations in Cancer Treatment: The Patented Work of Ira H. Pastan
Introduction
Ira H. Pastan is a prominent figure in the field of molecular biology and cancer research, based in Potomac, MD. With a prolific portfolio comprising 88 patents, Pastan has made significant contributions to the development of innovative therapies aimed at treating various cancers. His work highlights the intersection of science and technology, pushing the boundaries of how we understand and combat disease.
Latest Patents
Among his most recent patents is the development of immunotoxins with an albumin binding domain. This innovative molecule comprises multiple domains: a targeting moiety, an albumin binding domain, a furin cleavage sequence, and an optionally substituted Domain III from exotoxin A. This patent not only includes the molecule itself but also related nucleic acids, expression vectors, host cells, and pharmaceutical compositions that detail methods for treating cancer in mammals and inhibiting the growth of target cells.
Another significant patent involves cross-species single domain antibodies that target mesothelin, a protein commonly associated with solid tumors. This research highlights camel single-domain monoclonal antibodies specifically designed to bind human and mouse mesothelin. The innovative aspects of this patent include chimeric antigen receptor (CAR) T cells and antibody conjugates utilizing these mesothelin-specific antibodies, providing promising avenues for diagnosing and treating mesothelin-positive cancers.
Career Highlights
Ira H. Pastan has enjoyed a distinguished career, marked by an unwavering commitment to harnessing the potential of immunotherapy in oncology. He has had tenures at esteemed organizations such as the United States Department of Health and Human Services, where he contributed his expertise in developing therapies that aim to improve cancer treatment outcomes. His innovative approach has earned him recognition and respect within the scientific community.
Collaborations
Throughout his career, Pastan has collaborated with several esteemed colleagues, including Masanori Onda and Byungkook Lee. These collaborations have fostered advancements in cancer therapeutics, combining diverse expertise to push the frontiers of medical science and enhance treatment precision.
Conclusion
Ira H. Pastan's contributions to science through his patents underscore the critical role of innovation in combating diseases, especially cancer. His work on immunotoxins and antibody-based therapies has not only advanced our understanding of targeted treatment but also paved the way for future research aimed at eradicating cancer. As he continues to push the boundaries of what is possible in the realm of molecular biology, Pastan serves as an inspiration to current and future generations of inventors and researchers.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile